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INTRODUCTION
Two new antibody-drug conjugates (ADCs) incorporating different ultratoxic (picomolar potency) drugs have been approved, leading to further development of other ADCs based on similar principles, including use of ultratoxic drugs (1) (2) (3) . Our group has taken an alternative approach, selecting a moderately toxic agent, SN-38, a topoisomerase I inhibitor that is the active metabolite of irinotecan, an approved drug with well-known but complex pharmacology (4) (5) (6) . Several linkers for conjugating were evaluated for release from the IgG at varying rates, from several hours to days (4, 5, 7, 8) . The linker selected, designated CL2A, resulting in an intermediate conjugate stability in serum, was attached to the hydroxyl group on SN-38's lactone ring, and contains a short polyethylene glycol moiety to enhance solubility (5, 7) . The active form of SN-38 was liberated when the carbonate bond between the linker and SN-38 was cleaved, which occurred at low pH, such as that found in lysosomes, as well as the tumor microenvironment, or possibly through enzymatic degradation.
The antibody chosen for this ADC targeted a tumor-associated antigen, Trop-2 (trophoblast cellsurface antigen) (7), using the humanized RS7 monoclonal antibody that was shown previously to internalize (9) . Trop-2 is over-expressed on many epithelial tumors, particularly more aggressive types (10) (11) (12) , but is also present on a number of normal tissues. However, preclinical studies in monkeys that express the antigen observed only dose-limiting neutropenia and diarrhea with this new ADC, with no evidence of appreciable toxicity to the Trop-2-expressing normal tissues (7) . Therefore, a Phase I clinical trial was initiated to determine the maximum tolerated and optimal doses of this novel ADC in heavily-pretreated patients with diverse, relapsed/refractory, metastatic epithelial tumors. This trial was registered at ClinicalTrials.gov (NCT01631552).
Research. 
MATERIALS and METHODS

Entry criteria
Patients were enrolled after approval from the Institutional Review Boards and obtaining written informed consent from the patients. The primary objective was to determine the safety and tolerability of sacituzumab govitecan (IMMU-132) as a single agent. The trial was designed as a standard 3 + 3 Phase I design, starting at a dose of 8 mg/kg per injection, with dosages given weekly for 2 weeks in a 3-week treatment cycle.
Male and non-pregnant, non-lactating females ≥ 18 years of age were eligible if they had a diagnosis of one of thirteen different types of epithelial tumors. Although no pre-selection based on Trop-2 expression was required, Trop-2 expression in >75% of the cases based on immunohistology studies on archival specimens was found. Patients were required to have measurable metastatic disease (no single lesions ≥ 5 cm) and had relapsed or were refractory to at least one approved standard chemotherapeutic regimen for that indication. Other key criteria included adequate (grade ≤ 1) hematology, liver and renal function, and no known history of anaphylactic reactions to irinotecan, or grade ≥3 gastrointestinal toxicity to prior irinotecan or other topoisomerase-I treatments. Since patients with such diverse diseases were allowed, prior irinotecan therapy was not a prerequisite. Patients with Gilbert's disease or those who had not tolerated previously administered irinotecan or with known CNS metastatic disease were excluded. Additional details are included in Supplementary Information online.
Study design
Baseline evaluations were performed within 4 weeks of the start of treatment (see Supplementary Information online for studies performed), with regular monitoring of blood counts, serum chemistries, vital signs, and adverse events. Anti-antibody and anti-SN-38 antibody reactions were measured by ELISA by the sponsor, with samples taken at baseline and then prior to the start of every even-numbered treatment cycle. The first CT examination was obtained 6-8 weeks from the start of treatment and then continued at 8-to 12-week intervals until progression. Additional follow-up was required only to monitor any ongoing treatment-related toxicity. Toxicities were graded using the NCI CTCAE version 4.0, and efficacy assessed by RECIST 1.1.
An ELISA to detect Trop-2 in serum was developed that has a sensitivity of 2 ng/mL, but after testing 12 patients and finding no evidence of circulating Trop-2, no further screening was performed.
Although not an eligibility criterion, specimens of previously archived tumors were requested for Trop-2 determination by immunohistology, using a goat polyclonal antibody anti-human Trop-2 (R&D Systems, Minneapolis, MN), since the epitope recognized by the ADC's antibody, hRS7, is not preserved in formalin-fixed, paraffin-embedded sections (9). Staining is described in Supplemental Information online.
Therapeutic regimen
Reconstituted sacituzumab govitecan was infused over 2-3 h (100 mg of antibody contained ~1.6 mg of SN-38, with a mean drug:antibody ratio [DAR] of 7.6:1). Prior to the start of each infusion, most patients received acetaminophen, anti-histamines (H1 and H2 blockers), and dexamethasone.
Prophylactic use of anti-emetics or anti-diarrheal medications was prohibited. Therapy consisted of 2 consecutive doses given on days 1 and 8 of a 3-week treatment cycle, with the intent to allow patients to continue treatment for up to 8 cycles (i.e., 16 treatments) unless there was unacceptable toxicity or progression. Patients showing disease stabilization or response after 8 cycles could continue treatments.
Dose-limiting toxicity (DLT) was defined as grade ≥3 febrile neutropenia of any duration, grade 3 thrombocytopenia with significant bleeding or grade 4 thrombocytopenia ≥ 5 days, any grade 3 nausea, vomiting or diarrhea that persisted for >48 h despite optimal medical management, or grade 4
Research. (life threatening) nausea, vomiting or diarrhea of any duration, or any other grade ≥ 3 non-hematologic toxicity at least possibly due to study drug, as well as the occurrence of any grade 3 infusion-related reactions.
On a scheduled treatment day, any patient with grade ≥ 2 treatment-related toxicity, with the exception of alopecia, had the treatment delayed in weekly increments of up to 2 weeks. Treatment was reinitiated once toxicity had resolved to grade ≤ 1. The protocol also initially required all subsequent treatment doses to be reduced (25% if recovered within 1 week, 50% if within 2 weeks), but this was relaxed later in the trial when the protocol was amended to permit supportive care after the first cycle.
However, if toxicity did not recover within 3 weeks or worsened, treatment was terminated.
Importantly, a dose delay with reduction did not constitute a DLT, and therefore this allowed treatments to continue, but at a lower dose. Therefore, a patient requiring a dose delay/reduction who was able to continue treatment was not considered assessable for DLT, and was then replaced. only DLTs occurring during the first treatment cycle were considered. However, since a DLT event resulted in the termination of all further treatments, a secondary objective was to assess a dose that could be tolerated over multiple cycles of treatment with minimal dose delays or reductions. This dose level was designated the maximum acceptable dose, and required patients to tolerate a given dose level in the first cycle without having a delay or reduction during that cycle and leading up to the start of the second cycle.
Pharmacokinetics and immunogenicity
Blood samples were taken within ~30 min from the end of the infusion (e.g., peak) and then prior to each subsequent injection (e.g., trough). Samples were separated and sera frozen for determination of total IgG and sacituzumab govitecan concentrations, as well as anti-hRS7 and anti-SN- 
RESULTS
Patient characteristics
Twenty-five patients (52-60 years old, 10 male, 15 female) were enrolled. Their demographics and cancer types are summarized in Table 1 . Most patients had metastatic pancreatic cancer (PDC) (N = Immunohistology was performed on archival tissues from 17 patients, with 13 (76.4%) having 2+ to 3+ membrane and cytoplasmic staining on >10% of the tumor cells in the specimens; 1 specimen (5.9%) was 1+, and 3 specimens (17.6%) were negative. Several representative cases are provided in Supplementary Fig. S1 . All patients had metastatic disease with a median of 4 (range 1 -10) target lesions identified on baseline CT imaging and a median sum of largest tumor diameters of 9.7 cm (range 2.9 -29.8 cm). The patients received at least one prior chemotherapy regimen (median, 3 prior therapies), and eleven had received prior radiation therapy. Only 7 patients responded to their last prior therapy and the median duration of their response was 3 months (range, 1-11 months).
Additionally, 9 patients received prior anti-topoisomerase I therapy with either irinotecan (N=7) or topotecan (N=2), of whom 3 failed to respond to this prior therapy. Multiple sacituzumab govitecan treatments (median, 10 doses) were given until there was definitive evidence of disease progression by CT. One patient withdrew after receiving 1 dose because of generalized deterioration, but all other patients received ≥3 treatments.
Dose Assessment
At the starting dose level of 8.0 mg/kg, 3 patients were treated without DLT, dose delays, or reductions. At the next dose level of 12 mg/kg, 9 patients were enrolled because of protocol-required delays in administering the second dose were encountered. Five patients experienced a delay in cycle 1 (4 had a 1-week delay, with 2 given myeloid growth factor support, and 1 patient having a 2-week delay before being given a second dose). All but 1 of these patients received 12 mg/kg as their second dose.
Four of the nine patients at the 12 mg/kg dose level had the third dose that started the second cycle decreased to 9 mg/kg, and the second cycle was delayed 1 additional week in 3 patients. Despite these protocol-required delays/reductions, none of the 9 patients had a dose-limiting event during the first cycle (e.g., one had disease-related grade 3 hemoglobin after first dose, 2 with grade 3 neutropenia after first dose were given myeloid growth factors, 1 had grade 3 neutropenia after first dose that recovered without support, 2 had grade 3 neutropenia after second dose, 2 patients had grade 2 neutropenia after the first or second dose, and 1 patient had no adverse events), and therefore accrual to the 18 mg/kg dose level was allowed. Here, all three patients had dose delays after their first treatment, with only 1 patient receiving the second treatment at 18 mg/kg. Two patients had doselimiting grade 4 neutropenia, 1 after first dose, the other after the second 18 mg/kg dose, with this latter patient also experiencing grade 2 diarrhea. Therefore, with 0/9 patients having DLT in the first cycle at 12 mg/kg, this level was declared the MTD for a single-cycle regimen.
Additional dose-finding studies continued to refine the dose level that would allow multiple cycles to be given with minimal delay between treatments/cycles. Therefore, 4 more patients were enrolled at the 8 mg/kg dose level, and a new intermediate level of 10 mg/kg was opened. Of the initial three patients enrolled at 8 mg/kg, two CRC patients continued treatment at 8 mg/kg for a total of 31 and 11 treatments, while a PDC patient received three 8 mg/kg doses before dose reduction to 6 mg/kg because of a grade-2 neutropenia on the fourth dose, and then completed 3 more doses at this level before withdrawing due to disease progression. The additional 4 patients received 3 to 9 doses of 8 mg/kg before withdrawing with disease progression. Two of these patients received only 1 dose before a protocol-required reduction to 6 mg/kg, because of a grade-2 rash and neutropenia.
Five of the six patients enrolled at 10 mg/kg received 6 to 30 doses without reduction before withdrawing due to disease progression. One GC patient (#9) developed grade 3 febrile neutropenia as well as grade 4 hemoglobin after receiving 1 dose. While the febrile neutropenia was considered possibly-related to treatment, because it occurred shortly after the first dose, a perforation in the stomach lining was found to likely contribute to the grade 4 hemoglobin, and was considered unrelated to drug. Ultimately, the patient had rapid deterioration and died 4 weeks from the first dose.
Thus, while the overall results supported 12 mg/kg as the MTD, since 8 to 10 mg/kg doses were better tolerated in the first cycle and permitted repeated cycles with minimal toxicity, Phase II clinical studies are in progress to evaluate these 2 dose levels.
Adverse Events
There were 297 infusion of sacituzumab govitecan given over 2-3 h, with no infusion-related events. While more than half of the patients experienced fatigue, nausea, alopecia, diarrhea, and neutropenia considered at least likely related to treatment, these were mostly grade 1 and 2 ( Table 2) .
The most reported grade 3 or 4 toxicity was neutropenia (N = 9), but seven of these patients were treated initially at 12 and 18 mg/kg. Febrile neutropenia occurred in 2 patients, one was the GC patient (#9) already mentioned who received only one 10 mg/kg dose, and a second PDC patient (#19), who had received 4 doses of 12 mg/kg. Diarrhea was mild in most patients, with only three (12%) experiencing grade 3. Two occurred at the 12 mg/kg dose level, 1 after receiving 4 doses, and the other after the first dose, but this patient received 6 more doses at 12 mg/kg with only grade 2 diarrhea reported.
Subsequently, both patients were prescribed an over-the-counter anti-diarrheal and treatment continued. There were no other significant toxicities associated with sacituzumab govitecan, but two patients reported a grade 2 rash and 3 patients had a grade 1 pruritus. or PR (N = 18). Of the nine patients who received prior therapy containing a topoisomerase-I inhibitor, two had significant reductions of their target lesions (28% and 38%), 5 had stable disease, including 2 for sustained periods (4.1 and 6.9 months, respectively), whereas 2 progressed at their first assessment. 
Efficacy
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Trop-2 tissue expression
The potential utility of testing Trop-2 expression in archived samples from this small sampling of 17 patients with diverse cancers is insufficient for definitive assessment, primarily because most showed elevated expression. An overview of the IHC staining score vs. best response and time to progression is provided in Supplementary Fig. S2 .
PK and immunogenicity
Concentrations of sacituzumab govitecan and IgG in the 30-min serum sample are provided in Supplementary Table S1 , which show a general trend for the values to increase as the dose increased. Total SN-38 concentration in the 30-min serum sample of patient 15 was 3,930 ng/mL after the first dose in cycle 1 (C1D1), but when sacituzumab govitecan treatment was reduced to 9.0 mg/kg for the second dose of the first cycle (C1D2), the level decreased to 2,947 ng/mL (Figure 3, panel B) . A further reduction to 2,381 ng/mL was observed in the 6 th cycle, when the dose was further reduced to 6.0 mg/kg. The amount of free SN-38 in these samples ranged from 88 to 102 ng/mL (2.4% to 3.6% of total SN-38), illustrating that >96% of the SN-38 in the serum in these peak samples was bound to IgG.
Twenty-eight 30-min serum samples from 7 patients were analyzed by HPLC, with free SN-38 averaging 2.91 ± 0.91% of the total SN-38 in these samples. Free SN-38G concentrations measured in 4 patients never exceeded SN-38 levels, and were usually several-fold lower. For example, patient #25 had determinations assessed in the 30-min sample for 12 injections over 8 cycles of treatment. At a starting dose of 18 mg/kg, he had 5089 ng/mL of SN-38 in the acid-hydrolyzed sample (total SN-38) and just 155.2 ng/mL in the non-hydrolyzed sample (free SN-38; 3.0%). Free SN-38G (glucuronidated form) in this sample was 26.2 ng/mL, or just 14.4% of the total unbound SN-38 + SN-38G in the sample. The patient continued treatment at 13.5 mg/kg, with SN-38 averaging 3309.8 ± 601.8 ng/mL in the 11 remaining peak, acid-hydrolyzed samples, while free SN-38 averaged 105.4 ± 47.7 ng/mL (i.e., 96.8% bound to the IgG), and free SN-38G averaging 13.9 ± 4.1 ng/mL (11.6% of the total SN-38 + SN-38G). Importantly, in nearly all of the patients, concentrations of SN-38G in the acid-hydrolyzed and non-hydrolyzed samples were similar, indicating that none of the SN-38 bound to the conjugate was glucuronidated.
None of these patients had a positive baseline level (i.e., >50 ng/mL) or a positive antibody response to either the IgG or SN-38 over their course of treatment.
Discussion
Research. Trop-2 is expressed abundantly in many epithelial tumors, making it an antigen of interest for targeted therapies (10, 11) , especially since it is considered a prognostic marker and oncogene in several cancer types (7, (9) (10) (11) (12) . Although its expression in normal tissues and relationship to another wellstudied tumor-associated antigen, EpCAM, drew some initial words of caution regarding the safety of developing immunotherapeutics to Trop-2 (13), our studies in Cynomolgus monkeys that express Trop-2 in tissues similar to humans indicated sacituzumab govitecan was very well tolerated at a human equivalent dose totaling ~40 mg/kg (7). At higher doses, animals experienced neutropenia and diarrhea, known side-effects associated with SN-38 derived from irinotecan therapy, yet evidence for significant histopathological changes in Trop-2-expressing normal tissues was lacking (7). Thus, with other preclinical studies finding sacituzumab govitecan was potent at the low nanomolar level and effective in a variety of human epithelial tumor xenografts at non-toxic doses (7), a phase I trial was undertaken in patients who had failed one or more standard therapies for their diverse metastatic epithelial tumors.
A major finding of this study was that despite using a more conventional drug that is not considered as ultratoxic (drugs active in picomolar range, whereas SN-38 has potency in the low nanomolar range), the sacituzumab govitecan anti-Trop-2-SN-38 conjugate proved clinically to be therapeutically active in a wide range of solid cancers at doses with moderate and manageable toxicity, thus exhibiting an encouraging therapeutic index. A total of 297 doses of sacituzumab govitecan were given to 25 patients without incident; 4 patients received >25 injections. Importantly, no antibody response to the hRS7 IgG or SN-38 was detected, even in patients with multiple cycles of treatment for up to 12 months.
Although Trop-2 is expressed in low quantities in a variety of normal tissues (7), neutropenia was the only dose-limiting toxicity, with myeloid growth factor support used in 2 patients given ≥12 mg/kg of sacituzumab govitecan to expedite recovery and allow continuation of treatment in patients who had exhausted their therapy options. While the MTD was declared to be 12 mg/kg, 8.0 and 10.0 mg/kg dose levels were selected for further expansion, since patients were more likely to tolerate additional cycles at these levels with minimal supportive care, and responses were observed at these levels. Only 2 of 14 patients (14.3%) experienced grade-3 neutropenia at these dose levels. The grade 3 and 4 neutropenia incidence for irinotecan monotherapy given weekly or once every 3 weeks in a front-or second-line setting is reported as 14 to 26% (14) . With sacituzumab govitecan, only 1 patient at the 10 mg/kg dose level had grade-3 diarrhea. This incidence is lower than the 31% of patients given weekly x 4 doses of irinotecan who experienced grades 3 and 4 late diarrhea (14) . Other common toxicities attributed to sacituzumab govitecan included fatigue, nausea, and vomiting, most being grade 1 and 2, as well as alopecia. Two incidents of febrile neutropenia and one of grade 3 deep vein thrombosis also occurred at the 10 and 12 mg/kg dose levels. UGT1A1 monitoring was not initiated until after dose exploration was completed, so its contribution to toxicity cannot be reported now.
Patients enrolled in this trial were not pre-selected for Trop-2 expression, primarily because immunohistological assessments of tissue microarrays of diverse cancers (such as prostate, breast, pancreas, colorectal, and lung cancers) had indicated the antigen was present in >75% of the specimens (Immunomedics, data on file). In addition, Trop-2 was not found in the sera of 12 patients with diverse metastatic cancers, further suggesting that a serum assay would not be useful for patient selection.
Although we are attempting to collect archival specimens of the tumors from patients enrolled in the phase II trial, there is insufficient evidence at this time to suggest patient selection based on immunohistological staining will correlate with anti-tumor activity, so no patient enrichment based on Trop-2 expression has been undertaken. 
lesions before progressing 2.9, 4.3, and 7.1 months, respectively, from the onset of therapy, but only two are considered to have a PR according to RECIST 1.1, which requires a confirmatory scan. Thus, sixteen patients had SD, with 9 of these progressing after >4 months from the start of treatment.
Responses or disease stabilization occurred in 7 of 9 patients who had prior therapy with a topoisomerase I inhibitor-containing drug or regimen. Four of these failed to respond to their prior topoisomerase I inhibitor therapy (irinotecan or topotecan), yet sacituzumab govitecan induced tumor shrinkage in 2 of them: 12% in a patient with colon cancer (#4) and 36% in the other with SCLC (#22).
Thus, sacituzumab govitecan may be therapeutically active in those who failed or relapsed to a prior topoisomerase I-containing regimen, which is being examined further in the phase II study.
Although the largest number of patients enrolled in this trial had advanced pancreatic ductal cancer (N = 7; median time to progression 2.9 months; range, 1.0 to 4.0 months), there were encouraging reductions in target lesions and CA19-9 serum concentrations to suggest activity because of the advanced disease in these patients (15) . However, responses in patients with TNBC and SCLC are of particular interest, given the need for targeted therapies in these indications. Indeed, additional partial responses in patients with TNBC and SCLC observed in the ongoing expansion phase of this trial (16, 17) have suggested further emphasis on these cancers, but encouraging responses in NSCLC, EAC, UBC, and CRC are also being followed. Indeed, in a recent update of the ongoing phase II trial of sacituzumab govitecan, an overall response rate (PR) of 30%, with 40% clinical benefit rate (PR + SD ≥6 months) has been observed in 23 patients with metastatic TNBC (16). Long-term survival (15-20+ months) was observed for almost 25% (6/25) of the patients studied, and included 2 with PRs and 4 with SD, including patients with TNBC (N=2), CRC (N=3), and HRPC (N=1).
Analysis of the serum samples 30 min after the end of infusion showed >96% of the SN-38 was bound to the IgG. More detailed pharmacokinetics will be available when the phase II portion of the trial is completed. HPLC analysis also detected only trace amounts of free SN-38G in the serum, whereas with irinotecan therapy the AUC for the less active SN-38G is >4.5-fold higher than SN-38 (18) .
Comparison of SN-38 delivery in tumor-bearing animals given sacituzumab govitecan and irinotecan has indicated the SN-38 bound to the IgG is not glucuronidated, whereas in animals given irinotecan, >50% of the total SN-38 in the serum is glucuronidated (17) . More importantly, analysis of SN-38 concentrations were as much as 135-fold higher in Capan-1 human pancreatic cancer xenografts given sacituzumab govitecan than irinotecan (17) . Thus, sacituzumab govitecan has several distinct advantage over non-targeted forms of topoisomerase-I inhibitors: (i) a mechanism that selectively retains the conjugate in the tumor (anti-Trop-2 binding), and (ii) the targeted SN-38 also appears to be fully protected (i.e., non-glucuronidated and in the lactone form), such that any SN-38 accreted by the tumor cells either by the direct internalization of the conjugate or through its release into the tumor microenvironment from the conjugate bound to the tumor will be in its most potent form. These results suggest that a moderately-toxic, but well understood, cytotoxic agent, SN-38, can be effective as part of a tumor-targeting ADC, such as sacituzumab govitecan. But by administering an ADC with a moderatelytoxic drug conjugated at a high drug:antibody ratio (7.6:1), higher concentrations of SN-38 can be delivered to the cancers targeted, as suggested in the improved concentration of SN-38 achieved with sacituzumab govitecan compared to that released from irinotecan (17) .
In conclusion, this phase I experience has indicated that sacituzumab govitecan is tolerated with moderate and manageable toxicity, all related to the activity of SN-38, with no evidence of damage to normal tissues known to contain Trop-2. Importantly, sacituzumab govitecan is active in patients with diverse metastatic solid tumors, possibly even after failing prior therapy with topoisomerase-I inhibitors, which needs to be studied further. This clinical trial is continuing, focusing on starting doses of 8 and 10 mg/kg in patients with TNBC, SCLC, NSCLC and other cancers, even when these are not known to be responsive to topoisomerase I inhibitors. 
